{"version":"company-facts.v1","source":"https://secwatch.observer","generated_at":"2026-06-06T20:34:02.453626+00:00","company":{"ticker":"RXST","cik":1111485,"company_name":"RxSight, Inc."},"pagination":{"limit":100,"returned":7,"next_cursor":null},"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer","facts":[{"fact_type":"earnings_release","fact_key":"6dd1055b3af1be0506da6fb27d0b24193a054dcf","cik":1111485,"ticker":"RXST","company_name":"RxSight, Inc.","filed_at":"2026-05-06T23:59:59+00:00","payload":{"eps_text":"$(0.38) per basic and diluted share","guidance_signal":"reaffirmed","item_codes_triggered":["2.02"],"net_income_text":"net loss of $(15.9) million","period_text":"the quarter ended March 31, 2026","report_date":"2026-05-06","result_type":"reported_results","revenue_text":"sales of $30.9 million"},"claim":"RxSight, Inc. reported the quarter ended March 31, 2026 results: revenue sales of $30.9 million, net income net loss of $(15.9) million, EPS $(0.38) per basic and diluted share. Guidance reaffirmed.","evidence_excerpt":"– May 6, 2026 – RxSight, Inc. (NASDAQ: RXST) today reported financial results for the quarter ended March 31, 2026. Strategic Highlights and Recent Developments • Q1 sales of $30.9 million driven by 27,472 Light Adjustable Lens (LAL) units • 20 Light Delivery Devices (LDDs) sold in Q1, expanding the installed base to 1,154 units • Robust clinical data presented at","confidence":1.0,"filing_url":"https://secwatch.observer/filing/0001193125-26-208912","anchor_url":"https://secwatch.observer/filing/0001193125-26-208912#claim-6dd1055b3af1be0506da6fb27d0b24193a054dcf","edgar_index_url":"https://www.sec.gov/Archives/edgar/data/1111485/000119312526208912/0001193125-26-208912-index.htm"},{"fact_type":"material_agreement","fact_key":"1f0ccdf5d01d11913e94538dc02f45e4d46fc673","cik":1111485,"ticker":"RXST","company_name":"RxSight, Inc.","filed_at":"2024-05-09T23:59:59+00:00","payload":{"action":"entry","agreement_name":"Underwriting Agreement","agreement_type":"underwriting","counterparty":"BofA Securities, Inc., as representative of the several underwriters listed in Schedule 1 thereto (the \"Underwriters\")","effective_date":"2024-05-08","item_codes_triggered":["1.01"],"value_text":"approximately $93.2 million"},"claim":"RxSight, Inc. entered into Underwriting Agreement with BofA Securities, Inc., as representative of the several underwriters listed in Schedule 1 thereto (the \"Underwriters\") valued at approximately $93.2 million (effective 2024-05-08).","evidence_excerpt":"On May 8, 2024, RxSight, Inc. (the “Company”) entered into an underwriting agreement (the “Underwriting Agreement”) with BofA Securities, Inc., as representative of the several underwriters listed in Schedule 1 thereto (the “Underwriters”), pursuant to which the Company agreed to issue and sell 1,785,714 shares (the “Shares”) of the Company’s common stock, $0.001 par value per share (the “Common Stock”).","confidence":0.9,"filing_url":"https://secwatch.observer/filing/0001193125-24-135328","anchor_url":"https://secwatch.observer/filing/0001193125-24-135328#claim-1f0ccdf5d01d11913e94538dc02f45e4d46fc673","edgar_index_url":"https://www.sec.gov/Archives/edgar/data/1111485/000119312524135328/0001193125-24-135328-index.htm"},{"fact_type":"earnings_release","fact_key":"956b462a9eb842287ebd2554baaf9f5b4e3d4cd4","cik":1111485,"ticker":"RXST","company_name":"RxSight, Inc.","filed_at":"2024-05-06T23:59:59+00:00","payload":{"eps_text":"$(0.25) per basic and diluted share","guidance_signal":"raised","item_codes_triggered":["2.02"],"net_income_text":"$(9.1) million","period_text":"the three months ended March 31, 2024","report_date":"2024-05-06","result_type":"reported_results","revenue_text":"$29.5 million"},"claim":"RxSight, Inc. reported the three months ended March 31, 2024 results: revenue $29.5 million, net income $(9.1) million, EPS $(0.25) per basic and diluted share. Guidance raised.","evidence_excerpt":"following cataract surgery, today reported financial results for the three months ended March 31, 2024. Key Quarterly Highlights • Reported first quarter 2024 revenue of $29.5 million, an increase of 69% compared to the first quarter of 2023, reflecting: • The sale of 20,218 Light Adjustable Lenses (LAL®/LAL+TM), representing a 92% increase in procedure volume","confidence":0.95,"filing_url":"https://secwatch.observer/filing/0000950170-24-053553","anchor_url":"https://secwatch.observer/filing/0000950170-24-053553#claim-956b462a9eb842287ebd2554baaf9f5b4e3d4cd4","edgar_index_url":"https://www.sec.gov/Archives/edgar/data/1111485/000095017024053553/0000950170-24-053553-index.htm"},{"fact_type":"material_agreement","fact_key":"272d012cd7a750c918dee604375756e31f5df866","cik":1111485,"ticker":"RXST","company_name":"RxSight, Inc.","filed_at":"2024-04-23T23:59:59+00:00","payload":{"action":"amendment","agreement_name":"100 Columbia Amendment","agreement_type":"lease","counterparty":"Accuride International Inc.","effective_date":"2024-04-18","item_codes_triggered":["1.01"],"value_text":"$64,843 per month"},"claim":"RxSight, Inc. amended 100 Columbia Amendment with Accuride International Inc. valued at $64,843 per month (effective 2024-04-18).","evidence_excerpt":"On April 18, 2024, the Company entered into a Fifth Amendment to that certain Commercial Lease Agreement, dated August 31, 2015, as amended November 23, 2015, December 22, 2015, January 18, 2016, and November 12, 2016, with Accuride International Inc., for the property located at 100 Columbia in Aliso Viejo, California (the “100 Columbia Amendment”).","confidence":0.9,"filing_url":"https://secwatch.observer/filing/0000950170-24-046558","anchor_url":"https://secwatch.observer/filing/0000950170-24-046558#claim-272d012cd7a750c918dee604375756e31f5df866","edgar_index_url":"https://www.sec.gov/Archives/edgar/data/1111485/000095017024046558/0000950170-24-046558-index.htm"},{"fact_type":"material_agreement","fact_key":"5153a04f642732f2b314580fe28ad0c1151bcb8d","cik":1111485,"ticker":"RXST","company_name":"RxSight, Inc.","filed_at":"2024-04-23T23:59:59+00:00","payload":{"action":"amendment","agreement_name":"5 Columbia Amendment","agreement_type":"lease","counterparty":"Clifford D. Downs","effective_date":"2024-04-18","item_codes_triggered":["1.01"],"value_text":"$30,701 per month"},"claim":"RxSight, Inc. amended 5 Columbia Amendment with Clifford D. Downs valued at $30,701 per month (effective 2024-04-18).","evidence_excerpt":"On April 18, 2024, the Company entered into Lease Amendment #2 to that certain Lease Agreement dated January 10, 2018, as amended on April 5, 2022, with Clifford D. Downs, for the property located at 5 Columbia in Aliso Viejo, California (the “5 Columbia Amendment”).","confidence":0.9,"filing_url":"https://secwatch.observer/filing/0000950170-24-046558","anchor_url":"https://secwatch.observer/filing/0000950170-24-046558#claim-5153a04f642732f2b314580fe28ad0c1151bcb8d","edgar_index_url":"https://www.sec.gov/Archives/edgar/data/1111485/000095017024046558/0000950170-24-046558-index.htm"},{"fact_type":"material_agreement","fact_key":"347484fb0476bcca81c31b5ad65b2c03373311f4","cik":1111485,"ticker":"RXST","company_name":"RxSight, Inc.","filed_at":"2024-04-23T23:59:59+00:00","payload":{"action":"entry","agreement_name":"125 Columbia Lease","agreement_type":"lease","counterparty":"BML Management, LLC","effective_date":"2024-04-18","item_codes_triggered":["1.01"],"value_text":"$41,579 per month"},"claim":"RxSight, Inc. entered into 125 Columbia Lease with BML Management, LLC valued at $41,579 per month (effective 2024-04-18).","evidence_excerpt":"On April 18, 2024, the Company entered into a Standard Industrial/Commercial Single-Tenant Lease – Net (the “125 Columbia Lease”) with BML Management, LLC, for an approximately 26,825 square foot industrial and research and development facility in Aliso Viejo, California.","confidence":0.9,"filing_url":"https://secwatch.observer/filing/0000950170-24-046558","anchor_url":"https://secwatch.observer/filing/0000950170-24-046558#claim-347484fb0476bcca81c31b5ad65b2c03373311f4","edgar_index_url":"https://www.sec.gov/Archives/edgar/data/1111485/000095017024046558/0000950170-24-046558-index.htm"},{"fact_type":"earnings_release","fact_key":"299b8f8e976cf8619016c3e11de05ff52fd9c091","cik":1111485,"ticker":"RXST","company_name":"RxSight, Inc.","filed_at":"2024-02-28T23:59:59+00:00","payload":{"eps_text":null,"guidance_signal":"reaffirmed","item_codes_triggered":["2.02"],"net_income_text":null,"period_text":"the three and twelve months ended December 31, 2023","report_date":"2024-02-28","result_type":"reported_results","revenue_text":null},"claim":"RxSight, Inc. updated its the three and twelve months ended December 31, 2023 guidance (reaffirmed).","evidence_excerpt":"On February 28, 2024, RxSight, Inc. (the “ Company ” ) issued a press release announcing its results of operations and financial condition for the three and twelve months ended December 31, 2023.","confidence":0.9,"filing_url":"https://secwatch.observer/filing/0000950170-24-022053","anchor_url":"https://secwatch.observer/filing/0000950170-24-022053#claim-299b8f8e976cf8619016c3e11de05ff52fd9c091","edgar_index_url":"https://www.sec.gov/Archives/edgar/data/1111485/000095017024022053/0000950170-24-022053-index.htm"}]}